Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ACAD |
---|---|---|
09:32 ET | 11985 | 18.17 |
09:33 ET | 1650 | 18.185 |
09:35 ET | 770 | 18.24 |
09:37 ET | 1000 | 18.2394 |
09:39 ET | 1347 | 18.265 |
09:42 ET | 3389 | 18.27 |
09:44 ET | 5750 | 18.3 |
09:46 ET | 800 | 18.266923 |
09:48 ET | 4408 | 18.33 |
09:50 ET | 1901 | 18.34 |
09:51 ET | 1900 | 18.35 |
09:53 ET | 1788 | 18.39 |
09:55 ET | 300 | 18.345 |
09:57 ET | 200 | 18.35 |
10:00 ET | 539 | 18.32 |
10:02 ET | 1550 | 18.39 |
10:04 ET | 10891 | 18.35 |
10:06 ET | 330 | 18.335 |
10:08 ET | 1172 | 18.32 |
10:09 ET | 10992 | 18.35 |
10:11 ET | 640 | 18.37 |
10:13 ET | 403 | 18.36 |
10:15 ET | 1756 | 18.35 |
10:18 ET | 2200 | 18.3729 |
10:20 ET | 1167 | 18.36 |
10:22 ET | 4061 | 18.37 |
10:24 ET | 1700 | 18.34 |
10:26 ET | 1250 | 18.32 |
10:27 ET | 4800 | 18.34 |
10:29 ET | 700 | 18.3768 |
10:31 ET | 100 | 18.37 |
10:33 ET | 1289 | 18.33 |
10:36 ET | 708 | 18.35 |
10:38 ET | 3113 | 18.31 |
10:40 ET | 6081 | 18.29 |
10:42 ET | 4540 | 18.3 |
10:44 ET | 900 | 18.3 |
10:45 ET | 1272 | 18.3 |
10:47 ET | 1623 | 18.34 |
10:49 ET | 1000 | 18.33 |
10:51 ET | 200 | 18.325 |
10:54 ET | 500 | 18.31 |
10:56 ET | 500 | 18.32 |
10:58 ET | 1811 | 18.32 |
11:00 ET | 8400 | 18.3 |
11:02 ET | 2546 | 18.275 |
11:03 ET | 11407 | 18.31 |
11:05 ET | 900 | 18.315 |
11:07 ET | 300 | 18.315 |
11:09 ET | 100 | 18.3 |
11:12 ET | 1105 | 18.3 |
11:14 ET | 7353 | 18.27 |
11:16 ET | 2093 | 18.25 |
11:18 ET | 111 | 18.25 |
11:20 ET | 1573 | 18.2529 |
11:21 ET | 1941 | 18.27 |
11:23 ET | 2126 | 18.22 |
11:25 ET | 200 | 18.22 |
11:27 ET | 2840 | 18.25 |
11:30 ET | 500 | 18.225 |
11:32 ET | 516 | 18.25 |
11:34 ET | 600 | 18.25 |
11:36 ET | 500 | 18.26 |
11:38 ET | 400 | 18.27 |
11:39 ET | 1387 | 18.24 |
11:41 ET | 300 | 18.24 |
11:43 ET | 684 | 18.21 |
11:48 ET | 1295 | 18.19 |
11:50 ET | 1036 | 18.16 |
11:52 ET | 560 | 18.125 |
11:54 ET | 2409 | 18.13 |
11:56 ET | 414 | 18.125 |
11:57 ET | 421 | 18.115 |
11:59 ET | 689 | 18.11 |
12:01 ET | 400 | 18.11 |
12:03 ET | 1671 | 18.08 |
12:06 ET | 1200 | 18.09 |
12:08 ET | 900 | 18.11 |
12:10 ET | 200 | 18.1059 |
12:12 ET | 800 | 18.14 |
12:14 ET | 1270 | 18.11 |
12:15 ET | 902 | 18.1 |
12:17 ET | 6082 | 18.05 |
12:19 ET | 1690 | 18.025 |
12:21 ET | 928 | 18.015 |
12:24 ET | 1752 | 18.015 |
12:26 ET | 3400 | 17.995 |
12:28 ET | 1917 | 18 |
12:30 ET | 4527 | 18.03 |
12:32 ET | 1185 | 18.04 |
12:33 ET | 291 | 18.06 |
12:35 ET | 1806 | 18.05 |
12:37 ET | 600 | 18.04 |
12:39 ET | 665 | 18.04 |
12:42 ET | 300 | 18.04 |
12:44 ET | 3104 | 18.07 |
12:46 ET | 2604 | 18.08 |
12:48 ET | 650 | 18.08 |
12:50 ET | 1584 | 18.082 |
12:51 ET | 1000 | 18.08 |
12:53 ET | 1523 | 18.08 |
12:55 ET | 400 | 18.09 |
12:57 ET | 2856 | 18.05 |
01:00 ET | 1611 | 17.9832 |
01:02 ET | 606 | 17.96 |
01:04 ET | 1569 | 17.99 |
01:06 ET | 730 | 18.0078 |
01:08 ET | 700 | 18 |
01:09 ET | 200 | 17.98 |
01:11 ET | 581 | 17.975 |
01:13 ET | 2106 | 17.97 |
01:15 ET | 2562 | 17.98 |
01:18 ET | 2078 | 17.96 |
01:20 ET | 580 | 17.96 |
01:22 ET | 900 | 17.97 |
01:24 ET | 2051 | 17.95 |
01:27 ET | 700 | 17.96 |
01:29 ET | 665 | 17.965 |
01:31 ET | 1159 | 17.975 |
01:33 ET | 4834 | 17.95 |
01:36 ET | 432 | 17.945 |
01:38 ET | 1874 | 17.95 |
01:40 ET | 1976 | 17.95 |
01:42 ET | 100 | 17.95 |
01:44 ET | 1321 | 17.94 |
01:45 ET | 1195 | 17.96 |
01:47 ET | 886 | 17.99 |
01:49 ET | 100 | 18.02 |
01:51 ET | 600 | 18.01 |
01:54 ET | 2000 | 18.03 |
01:56 ET | 1396 | 18.01 |
01:58 ET | 742 | 18.03 |
02:00 ET | 1100 | 18 |
02:02 ET | 300 | 18 |
02:03 ET | 3100 | 18.02 |
02:05 ET | 2000 | 17.99 |
02:07 ET | 403 | 17.975 |
02:09 ET | 24145 | 17.99 |
02:12 ET | 1715 | 18.02 |
02:14 ET | 200 | 18.02 |
02:16 ET | 400 | 18.01 |
02:18 ET | 1000 | 18 |
02:20 ET | 2354 | 18.03 |
02:21 ET | 2895 | 18.04 |
02:23 ET | 1075 | 18.08 |
02:25 ET | 973 | 18.1 |
02:27 ET | 600 | 18.085 |
02:30 ET | 1884 | 18.09 |
02:32 ET | 1501 | 18.085 |
02:34 ET | 500 | 18.11 |
02:36 ET | 105 | 18.1 |
02:38 ET | 400 | 18.11 |
02:39 ET | 853 | 18.12 |
02:41 ET | 1100 | 18.105 |
02:43 ET | 600 | 18.11 |
02:45 ET | 2695 | 18.091 |
02:48 ET | 2276 | 18.095 |
02:52 ET | 779 | 18.1 |
02:54 ET | 1010 | 18.11 |
02:56 ET | 1999 | 18.075 |
02:57 ET | 4000 | 18.08 |
02:59 ET | 1744 | 18.09 |
03:01 ET | 4700 | 18.15 |
03:03 ET | 1897 | 18.13 |
03:06 ET | 2505 | 18.115 |
03:08 ET | 2922 | 18.1183 |
03:10 ET | 2239 | 18.11 |
03:12 ET | 1000 | 18.115 |
03:14 ET | 600 | 18.11 |
03:15 ET | 4195 | 18.119 |
03:17 ET | 8231 | 18.1 |
03:19 ET | 2000 | 18.09 |
03:21 ET | 2422 | 18.03 |
03:24 ET | 300 | 18.03 |
03:26 ET | 1553 | 18.03 |
03:28 ET | 1041 | 17.979 |
03:30 ET | 2662 | 17.99 |
03:32 ET | 1200 | 17.96 |
03:33 ET | 4107 | 17.93 |
03:35 ET | 2300 | 17.91 |
03:37 ET | 4311 | 17.899 |
03:39 ET | 4521 | 17.865 |
03:42 ET | 2125 | 17.87 |
03:44 ET | 2188 | 17.875 |
03:46 ET | 12584 | 17.91 |
03:48 ET | 705 | 17.94 |
03:50 ET | 4863 | 17.92 |
03:51 ET | 5809 | 17.95 |
03:53 ET | 7087 | 17.945 |
03:55 ET | 6808 | 17.96 |
03:57 ET | 11511 | 17.87 |
04:00 ET | 289743 | 17.93 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
ACADIA Pharmaceuticals Inc | 3.0B | 23.1x | --- |
Azenta Inc | 2.2B | -16.3x | --- |
Amicus Therapeutics Inc | 3.2B | -30.3x | --- |
Catalyst Pharmaceuticals Inc | 2.8B | 19.7x | --- |
Veracyte Inc | 3.0B | -264.7x | --- |
Beam Therapeutics Inc | 2.5B | -16.2x | --- |
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.0B |
---|---|
Revenue (TTM) | $929.2M |
Shares Outstanding | 165.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.43 |
EPS | $0.78 |
Book Value | $2.62 |
P/E Ratio | 23.1x |
Price/Sales (TTM) | 3.3 |
Price/Cash Flow (TTM) | 21.5x |
Operating Margin | 12.08% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.